Objectives

- Review 2010 FCDS core data collection requirements
- Discuss FCDS 2010 Implementation Guide, Timeline and Data Standard Recommendations
- Review new and retired data item requirements
- Review format changes and changed data items
- Introduce new and revised abstracting/coding manuals and other references.

The Nitty Gritty

- Routine operational changes including the required use of new or substantially revised reference manuals, abstracting and coding instructions, new data collection rules and requirements, and new electronic help tools have introduced substantive changes for 2010 – even more than have infrastructure changes (data item/record layout).
- However, the degree to which data item coding have evolved to unique site/histology specific coding schema suggests these changes will be far reaching.
2010 Changes in Cancer Reporting

- 2010 standards developed in response to a wide range of issues introduced by an unrestrained set of constituents and standard setting organizations.

- The introduction of a new or changed electronic file structure, data transmission guidelines, record layout, or any change to data collection instructions, coding rules or abstractor tools that serve as a trade or industry standard has potential consequences.

- 2010 changes include ALL of the above.

Revisions to data collection requirements and data system design require close attention to transition to NAACCR Data Collection Standards – Volume II, Version 12 in an efficient and timely manner.

- Delays in implementation may result in inconsistent and/or incomplete statewide data collection.

- Implementation must be evaluated by each cancer program, central cancer registry, software vendor, and reporting facility during the planning process.

NAACCR and FCDS 2010 Implementation Guidelines include infrastructure upgrades and changes to data collection and transmission standards, namely the NAACCR record length and layout, and specifically:

- Addition of 126 data items
- Changes to 103 data items
- Retirement of 69 data items
- Field length expanded for many data items and text
- Record length expanded to 22,824 characters
New Abstracting Tools and Coding Manuals

- 2010 FCDS Data Acquisition Manual
- CSv2 – Collaborative Stage Data Collection System
- 2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual, v1.6
- Hematopoietic Database, v1.6
- SEER*Rx, v1.4.1
- 2010 FORDS

Note: Updates to the 2007 Multiple Primary and Histology Coding Rules were delayed until 2011.

Abstracting Tools/Coding Manuals

Collaborative Stage Data Collection System, v2 (CSv2)
- CSv2 is a coding system
- CSv2 is NOT a staging system
- CSv2 is based on AJCC 7th Edition (staging system)
- 152 “chapters” or site-specific schema
- Effective January 1, 2010
- No printed manuals
- PDF and XML

http://cancerstaging.org
- Includes instructions, rules, site-specific coding schema and help features designed to assist the registrar in using historical and new CS variables.

Abstracting Tools/Coding Manuals

Collaborative Stage Data Collection System, v2 (CSv2)
- Once CSv2 is installed, it will be the only CS version used for all cases / all diagnosis years.

- All CSv1 data to be converted to be CSv2 compatible
- 2004-2009 will derive AJCC 6th edition TNM/stage
- 2010 + will derive AJCC 6th and 7th edition TNM/stage
- All cases will derive SEER Summary Stage 1977
- All cases will derive SEER Summary Stage 2000

Your software vendors should be providing this conversion program to you as part of your upgrade.
Abstracting Tools/Coding Manuals

- 2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the companion Hematopoietic Database – latest version v1.6
- WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, 2008 is the foundation for both the Heme/Lymph Coding Manual and Database
- ICD-O-3 is no longer primary coding reference
- Transformations now abstracted as new primary

Abstracting Tools/Coding Manuals

- Diagnostic Confirmation designation has changed to include the basis of laboratory/tumor markers and immunohisto-cytochemistry results.
- 34 new ICD-O codes not found in ICD-O-3
- 3 new reportable conditions (behavior from /1 to /3)
  - 9751/3 - Langerhans cell histiocytosis
  - 9831/3 - T-cell large granular lymphocytic lymphoma/chronic lymphoproliferative disorder of NK-cells
  - 9975/3 - Myeloproliferative neoplasm, NOS; myelodysplastic/myeloproliferative neoplasm, unclassifiable

New Data Items

- Lymph-vascular Invasion – present/absent/NA/unk
- CS Site-Specific Factor 7–24 – content varies widely
- CS Site-Specific Factor 25 – schema discriminator
- RX Summ – Treatment Status – tx given, not given, wait
- Other new items not required by FCDS
New Data Items for FCDS

- Addr at DX – State
- Addr Current – State
- Code Source: USPS
  - US State abbreviations
  - Canadian provinces
- County at DX
- County Current
- Code Source: FIPS county codes

Date Format Change

- Date Format Old – MMDDYYYY
- Date Format New – YYYYMMDD
  - 20090723 – Full Date
  - 200907 – Unknown Day
  - 2009 – Unknown Month and Day
- No More 0’s, 8’s or 9’s
- Date conversions should be part of software upgrade and most will not be visible to users – but be aware!!

Date Format Change

- Date Flags – Since only actual known dates are now entered in date items, date flags are used to explain why there is no appropriate value in the corresponding date field.
- Sample Date Flags
  - Date of Birth Flag
  - Date of Diagnosis Flag
  - Date of 1st Contact Flag
  - Rx Date Surgery Flag
  - Rx Date Radiation Flag
  - Rx Date Chemo Flag
  - Rx Date Hormone Flag
Field Length Changes

- Name Fields – 40 characters
  - First, Middle, Last, Maiden, Alias
  - Blanks, spaces, hyphens, apostrophe allowed

- Address – City – 50 characters
  - Addr at DX – City
  - Addr Current – City

- Address – No & Street/Supplemental – 60 characters
  - Addr at DX – No & Street
  - Addr Current – No & Street
  - Addr at DX – Supplemental
  - Addr Current – Supplemental

Field Length Changes

- Text Field – 60 characters
  - Place of Diagnosis

- Text Fields – 100 characters
  - Primary Site Title, Histology Title, Occupation, Industry

- Text Fields – 1000 characters
  - Diagnostic Workup Text – PE, Lab, Scopes, Path
  - Staging Text – Staging, OP, X-ray/Scan
  - Treatment Text – Surgery, Rad, Chemo, Hormone, BRM, Other
  - Other Text – Remarks

Field Length Changes

- AJCC TNM – 4 characters

<table>
<thead>
<tr>
<th>Clin T</th>
<th>Clin N</th>
<th>Clin M</th>
<th>Clin Stage Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Path T</td>
<td>Path N</td>
<td>Path M</td>
<td>Path Stage Group</td>
</tr>
</tbody>
</table>

- CS Fields – 3 characters
  - CS Extension
  - CS Lymph Nodes
  - Conversion required as part of implementation
**Miscellaneous Revised Items**

- **Laterality** – 1 new code
  - 5 – Paired Site – midline tumor

- **Race** – 3 new codes
  - Deleted code 09 (Asian Indian, Pakistani)
  - Added codes
    - 15 – Asian Indian, Pakistani, NOS
    - 16 – Asian Indian
    - 17 – Pakistani

- **Class of Case**
  - Expanded to 2 characters
  - More clear separation of Analytic / Non-analytic
    - Codes 00–22: Analytic Case – Dx/Tx – 1st Course
    - Codes 30–99: Non-Analytic Case
      - Codes 30–38 – patient physically seen at facility
      - Codes 40–49 – patient never seen at facility
      - Code 99 – unknown

- **Diagnostic Confirmation**
  - Instructions for Solid Tumors – no change
  - Instructions for Heme/Lymph Neoplasms – new!!
    - Changed codes for = microscopically confirmed
  - Code 3 – Heme/Lymph Dx Confirmation
    - Positive histology PLUS
    - Positive immunophenotyping test
      - and/or
    - Positive genetic studies
Retired Data Items

- FCDS unique items stored in state-specific area
- Many of the historical data items have been moved
- Florida has adopted national standards for several items
  - FCDS Tobacco use
  - FCDS Address Fields - county, state geocodes
  - FCDS Facility Number
  - FCDS Accession Number
  - ICD-O-2 Histology
  - ICD-O-2 Behavior
  - RX Summ Date Transplnt/Endocr

Software Availability

- ERS
- C/NET
- Elekta/METRIQ
- Other Vendor Software
- FCDS IDEA – Single Entry
- FCDS IDEA – Batch Upload
- FDCS IDEA - Upload Test - Vendor Batch Upload Test
  - Provides a self-administered Pre-Approval Process for you to pre-test your first submission of v12 data

FCDS IDEA

- New look for FCDS IDEA
- Some minor procedural changes in terms of data submission, edits, corrections, follow-back, etc.
- Facility Pre-Approval Process for v12 submission
- You will likely see some new or different edits
- You may see goofy data or unusual edit failures
- Call us if something looks out of place or incorrect
Edits / EDITS
- FCDS has always used EDITS logic plus Florida edits
- FCDS to adopt standard EDITS Metafile in 2010
- FCDS will provide a Florida EDITS Metafile that any vendor can use directly with their registry application
- Florida EDITS Metafile has been tested and is now ready for application use by cancer registry vendors
- Does not affect processing of edits/corrections

FCDS Core Requirements
- FCDS 2010 Implementation Guideline, v12
  - Revised May 24, 2010
- FCDS Record Layout in 2010 DAM
- New Instructions and Manuals
  - Heme/Lymph
  - FCDS DAM
  - CSv2 Instructions
    - CSv2 Core Data Items
    - CSv2 Site Specific Schema
    - CSv2 Site Specific Factors

FCDS CSv2 Core/SSF Required
- The FCDS CSv2 Site Specific Factors and CSv2 core data collection and coding requirements are not the same as CoC, SEER, or NPCR.
- FCDS requirements are based on NPCR core requirements for CSv2 and SFFs plus a few
  - Historically collected (CSv1 SSF / still relevant)
  - Required to assign stage element (T, N or M)
  - Required to assign stage group (Stage I, IA...)
  - Required to assign Summary Stage
What is a SSF Discriminator?

<table>
<thead>
<tr>
<th>Discriminator (SSF25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BileDuctsDistal</td>
</tr>
<tr>
<td>BileDuctsPerihilar</td>
</tr>
<tr>
<td>CysticDuct</td>
</tr>
<tr>
<td>EsophagusGEJunction</td>
</tr>
<tr>
<td>LacrimalGland</td>
</tr>
<tr>
<td>LacrimalSac</td>
</tr>
<tr>
<td>MelanomaCiliaryBody</td>
</tr>
<tr>
<td>MelanomaIris</td>
</tr>
<tr>
<td>Nasopharynx</td>
</tr>
<tr>
<td>Peritoneum</td>
</tr>
<tr>
<td>PeritoneumFemaleGen</td>
</tr>
<tr>
<td>PharyngealTonsil</td>
</tr>
<tr>
<td>Stomach</td>
</tr>
</tbody>
</table>

C Sv2 and SSF Use

Legend

<table>
<thead>
<tr>
<th>Legend</th>
<th>FCDS Required (TNM/SS)/NPCR</th>
<th>COC Additional Required</th>
<th>No Standard</th>
<th>Required</th>
<th>N/A - Not Defined</th>
</tr>
</thead>
</table>

CoC Required SSF – Prostate

<table>
<thead>
<tr>
<th>SSF 1</th>
<th>PSA Lab Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSF 2</td>
<td>PSA Interpretation</td>
</tr>
<tr>
<td>SSF 3</td>
<td>Gleason Primary Pattern</td>
</tr>
<tr>
<td>SSF 4</td>
<td>Gleason Primary Pattern</td>
</tr>
<tr>
<td>SSF 5</td>
<td>Gleason Score on Needle Core</td>
</tr>
<tr>
<td>SSF 6</td>
<td>Gleason Score on Needle Core</td>
</tr>
<tr>
<td>SSF 7</td>
<td>Gleason Primary Pattern and Secondary Pattern Value on Needle Core Biopsy/TURP</td>
</tr>
<tr>
<td>SSF 8</td>
<td>Gleason Primary Pattern and Secondary Pattern on Prostatectomy/Autopsy</td>
</tr>
<tr>
<td>SSF 9</td>
<td>Gleason Primary Pattern and Secondary Pattern on Prostatectomy/Autopsy</td>
</tr>
<tr>
<td>SSF 10</td>
<td>Gleason Score on Prostatectomy/Autopsy</td>
</tr>
<tr>
<td>SSF 11</td>
<td>Gleason Tertiary Pattern Value on Prostatectomy/Autopsy</td>
</tr>
<tr>
<td>SSF 12</td>
<td>Number of Cores Positive</td>
</tr>
<tr>
<td>SSF 13</td>
<td>Number of Cores Examined</td>
</tr>
</tbody>
</table>
### FCDS Required SSF – Prostate

| SSF 1 | PSA Lab Value |
| SSF 3 | CS Extension – Pathologic Extension |
| SSF 8 | Gleason Score on Needle Core Biopsy/TURP |
| SSF 10 | Gleason Score on Prostatectomy/Autopsy |

### CoC Required SSF – Breast

| SSF 1 | Estrogen Receptor Assay (ERA) |
| SSF 2 | Progesterone Receptor Assay (PRA) |
| SSF 3 | Number of Positive Ipsilateral Level III Axillary LN |
| SSF 4 | Immunohistochemistry (IHC) of Regional LN |
| SSF 5 | Molecular Studies of Regional LN |
| SSF 7 | Nottingham or Bloom-Richardson (BR) Score/Grade |
| SSF 8 | HER2 IHC Test Lab Value |
| SSF 9 | HER2 IHC Test Interpretation |
| SSF 10 | HER2 FISH Test Lab Value |
| SSF 11 | HER2 FISH Test Interpretation |
| SSF 12 | HER2 CISH Test Lab Value |
| SSF 13 | HER2 CISH Test Interpretation |
| SSF 14 | HER2 Result of Other or Unknown Test |
| SSF 21 | Response to Neoadjuvant Therapy |
| SSF 22 | Multigene Signature Method |
| SSF 23 | Result/Score of Multigene Signature |

### FCDS Required SSF – Breast

| SSF 1 | Estrogen Receptor Assay (ERA) |
| SSF 2 | Progesterone Receptor Assay (PRA) |
| SSF 3 | Number of Positive Ipsilateral Level III Axillary LN |
| SSF 4 | Immunohistochemistry (IHC) of Regional LN |
| SSF 5 | Molecular Studies of Regional LN |
| SSF 7 | Nottingham or Bloom-Richardson (BR) Score/Grade |
| SSF 8 | HER2 IHC Test Lab Value |
| SSF 9 | HER2 IHC Test Interpretation |
| SSF 10 | HER2 FISH Test Lab Value |
| SSF 11 | HER2 FISH Test Interpretation |
| SSF 12 | HER2 CISH Test Lab Value |
| SSF 13 | HER2 CISH Test Interpretation |
| SSF 14 | HER2 Result of Other or Unknown Test |
CoC Required SSF – Lung

SSF 1 Separate Tumor Nodules/Ipsilateral Lung
SSF 2 Visceral Pleural Invasion (VPI)/Elastic Layer

FCDS Required SSF – Lung

SSF 1 Separate Tumor Nodules/Ipsilateral Lung

CoC Required SSF – Colon

SSF 1 Carcinoembryonic Antigen (CEA)
SSF 2 Clinical Assessment of Regional Lymph Nodes
SSF 3 Carcinoembryonic Antigen (CEA) Lab Value
SSF 4 Tumor Deposits
SSF 6 Circumferential Resection Margin (CRM)
SSF 8 Perineural Invasion
SSF 9 KRAS
FCDS Required SSF – Colon

SSF 2  Clinical Assessment of Regional Lymph Nodes

CoC Required SSF – Bladder

SSF 1  WHO/ISUP Grade
SSF 2  Size of Metastasis in Lymph Nodes
SSF 3  Extranodal Extension of Regional Lymph Nodes

FCDS Required SSF – Bladder

SSF 2  Size of Metastasis in Lymph Nodes
CoC Required SSF – Brain

<table>
<thead>
<tr>
<th>SSF 1</th>
<th>WHO Grade Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSF 4</td>
<td>MGMT – Methylation of MGMT</td>
</tr>
<tr>
<td>SSF 5</td>
<td>Gene Deletions 1p</td>
</tr>
<tr>
<td>SSF 6</td>
<td>Chromosome 19q; Loss of Heterozygosity (LOH)</td>
</tr>
</tbody>
</table>

FCDS Required SSF – Brain

None     None

Melanoma

- 32 Site Specific Schema for Melanoma
  - Skin – all skin sites
  - Head and Neck – buccal mucosa, floor of mouth, nasopharynx, oropharynx, nasal cavity, sinus, etc.
  - Eye – choroid, ciliary body,
  - Other – conjunctiva, epiglottis, lip, larynx
- SSF required is different depending on schema
### CoC Required SSF – Melanoma Skin

<table>
<thead>
<tr>
<th>SSF</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Measured Thickness (Depth), Breslow Measurement</td>
</tr>
<tr>
<td>2</td>
<td>Ulceration</td>
</tr>
<tr>
<td>3</td>
<td>Clinical Status of Lymph Node Mets</td>
</tr>
<tr>
<td>4</td>
<td>LDH</td>
</tr>
<tr>
<td>5</td>
<td>LDH Value</td>
</tr>
<tr>
<td>6</td>
<td>LDH Upper Limit of Normal</td>
</tr>
<tr>
<td>7</td>
<td>Primary Tumor Mitotic Count/Rate</td>
</tr>
</tbody>
</table>

### FCDS Required SSF – Melanoma Skin

<table>
<thead>
<tr>
<th>SSF</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Measured Thickness (Depth), Breslow Measurement</td>
</tr>
<tr>
<td>2</td>
<td>Ulceration</td>
</tr>
<tr>
<td>3</td>
<td>Clinical Status of Lymph Node Mets</td>
</tr>
<tr>
<td>4</td>
<td>LDH</td>
</tr>
<tr>
<td>5</td>
<td>Primary Tumor Mitotic Count/Rate</td>
</tr>
</tbody>
</table>

### CoC Required SSF – Melanoma Ciliary Body

<table>
<thead>
<tr>
<th>SSF</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Measured Basal Diameter</td>
</tr>
<tr>
<td>3</td>
<td>Measured Thickness (Depth)</td>
</tr>
<tr>
<td>4</td>
<td>Size of Largest Metastasis</td>
</tr>
<tr>
<td>5</td>
<td>Chromosome 3 Status</td>
</tr>
<tr>
<td>6</td>
<td>Chromosome 6p Status</td>
</tr>
<tr>
<td>7</td>
<td>Chromosome 8q Status</td>
</tr>
<tr>
<td>8</td>
<td>Mitotic Count</td>
</tr>
<tr>
<td>9</td>
<td>Mean Diameter Nucleoli (MLN)</td>
</tr>
<tr>
<td>10</td>
<td>Extravascular Matrix Patterns, Loops</td>
</tr>
<tr>
<td>11</td>
<td>Extravascular Matrix Patterns, Networks</td>
</tr>
<tr>
<td>12</td>
<td>Microvascular Density (MVD)</td>
</tr>
<tr>
<td>13</td>
<td>PET Standardized Uptake Values (SUV)</td>
</tr>
<tr>
<td>14</td>
<td>Schema Discriminator (Ciliary Body/iris)</td>
</tr>
</tbody>
</table>

7/13/2010
FCDS Required SSF – Melanoma Ciliary Body

- SSF 2 Measured Basal Diameter
- SSF 3 Measured Thickness (Depth)
- SSF 4 Size of Largest Metastasis
- SSF 25 Schema Discriminator (Ciliary Body/Iris)

CoC Required SSF – Melanoma Sinus

- SSF 1 Size of lymph Nodes
- SSF 3 Levels I-III, LN for H&N
- SSF 4 Levels IV-V and Retropharyngeal LN for H&N
- SSF 5 Levels VI-VII and Facial LN for H&N
- SSF 6 Parapharyngeal, Parotid, and Suboccipital LN for H&N
- SSF 9 Extracapsular Extension, Pathologic, LN for H&N
- SSF 11 Measured Thickness (Depth)

FCDS Required SSF – Melanoma Sinus

- None None
Education and Training

- 7/22–7/23 – Introduction to New Materials
- FCDS Educational Webcasts – Thursdays @ 1pm–3pm
  - 7/29 – Collaborative Stage – Lung
  - 8/12 – Collaborative Stage – Breast
  - 8/26 – Collaborative Stage – Prostate
  - 9/9 – Collaborative Stage – Colon
  - 9/23 – Heme/Lymph Part I
  - 9/30 – Heme/Lymph Part II
- FCDS Educational Webcast Next Steps
- Other Training Resources
- Other Training Needs

---

**Meeting Name:** FCDS 2010 Educational Webcast Series  
**Date:** 7/29, 8/12, 8/26, 9/9, 9/23, and 9/30  
**Time:** 1pm–3pm EDT  
**Dial-in Number:** 877-807-5706  
**Participant Code:** 261452  
**Link to web session:** https://webmeeting.med.miami.edu/fcds2010educationseries/